Ben R. Taylor - 17 Feb 2026 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Signature
/s/ Kyle Nelson, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
17 Feb 2026
Net transactions value
-$82,911
Form type
4
Filing time
19 Feb 2026, 19:30:45 UTC
Previous filing
10 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Taylor Ben R Chief Financial Officer 41 S. RIO GRANDE STREET, SALT LAKE CITY /s/ Kyle Nelson, attorney-in-fact 19 Feb 2026 0001712276

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Tax liability $41,559 -11,908 -0.98% $3.49 1,208,775 17 Feb 2026 Direct F1
transaction RXRX Class A Common Stock Sale $41,352 -13,426 -1.1% $3.08 1,195,349 18 Feb 2026 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F2 This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.